![Paul F. Lubetkin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Paul F. Lubetkin first degree
Entity | Entity type | Industry | |
---|---|---|---|
Pharmasset, Inc.
![]() Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.
1
| Subsidiary | Pharmaceuticals: Other | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Paul F. Lubetkin via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
REGENERON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Chief Executive Officer | |
CHIASMA, INC. | Pharmaceuticals: Major | Chairman | |
OMRIX Biopharmaceuticals, Inc.
![]() OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Pharmaceuticals: Major | Chairman | |
Dartmouth College | College/University | Undergraduate Degree | |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman | |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Glycadia, Inc.
![]() Glycadia, Inc. Pharmaceuticals: MajorHealth Technology Glycadia, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for the prevention and treatment of kidney, eye, cardiovascular, and related diseases resulting from diabetes. The private company is based in Philadelphia, PA, and has subsidiaries in the United States. The company's science is based on recent discoveries concerning the causal role of circulating glycated. Glycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy, and cardiovascular disease. | Pharmaceuticals: Major | Chairman | |
RxFDP | Founder | ||
Pfizer Pharmaceuticals, Inc.
![]() Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin |
Statistics
International
United States | 12 |
United Kingdom | 2 |
Israel | 2 |
Denmark | 2 |
Canada | 2 |
Sectoral
Health Technology | 12 |
Consumer Services | 3 |
Commercial Services | 2 |
Operational
Chairman | 7 |
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Chief Administrative Officer | 1 |
Director of Finance/CFO | 1 |
Most connected contacts
Insiders | |
---|---|
Fredric D. Price | 16 |
- Stock Market
- Insiders
- Paul F. Lubetkin
- Company connections